Coologics, a clinical-stage medical device company, today announced the successful closing of their Seed round. The round was oversubscribed, demonstrating strong investor confidence in Coologics' vision and technology around its initial product, Vlisse.

The seed funding round secured over $3 million in investment, exceeding the initial target of $1.5 million. The funding was led by Prevail and Dream Ventures and saw material participation from two university alumni groups, Ohio State Early Investor Network and Illinois Ventures Illini Angels Program. The Company's CEO/founder, Dr. Kim Langdon and Chief Medical Officer, Dr. Nicole Williams are alumni of the Ohio State University and the University of Illinois, respectively.